Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
Merck’s anti-TL1A secures a ph. 2 hidradenitis suppurativa win
The study met its primary and secondary endpoints at week 16, informing phase 3 development for tulisokibart in HS.
Marissa Russo
Sep 30, 2026 10:20am
Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
Sep 28, 2026 7:59am
Merck and Daiichi pull lung cancer filing after FDA pushback
Sep 28, 2026 4:30am
Merck sees pivotal victory for $3B eye disease prospect
Sep 24, 2026 8:15am
DPHARM: How to address the clinical trial enrollment crisis?
Sep 17, 2026 11:52am
GSK’s ADC lays down marker for lung cancer scrap with Merck
Sep 12, 2026 7:00pm
